The strength of the UK's clinical trial sector is well recognised internationally. At present it is estimated that the UK accounts for over 40% of the medicinal products currently in late-stage clinical trials in Europe. In addition, the country's regulatory environment is viewed as providing a good balance between protecting human and environmental safety, and promoting innovation and entrepreneurial endeavour. These features are set to be highlighted at a unique event to be held at the Radisson Blu Hotel in Basel, Switzerland. The meeting is organised by the British‐Swiss Chamber of Commerce and UK Trade & Investment.
Entitled "New Clinical Trial Partnerships in the UK - Chances and Opportunities in the Future", the event focuses on the Swiss biopharma and pharmaceutical audience for clinical trials in the UK, specifically targeting decision-makers from the sector. The event will feature high-level speakers from both Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI). A special delegation from the Clinical Contract Research Association (CCRA) and Hoffmann-La Roche will also be attending. Following the seminar there will be time during an apéro for one-to-one meetings at the company stands between UK CROs and Swiss companies.
As well as providing an overview on the current environment for clinical trials in the UK and the opportunities for partnership, the event will feature a perspective on how the future landscape is evolving and a Q&A session. A number of initiatives are underway to bolster the UK's credentials for clinical research and pharmaceutical innovation. For example, the MHRA recently reviewed and put in place new regulatory processes for certain first in man studies with novel products, allowing timely but enhanced review. The MHRA holds a large number of scientific advice meetings nationally each year and is amongst the leading Member States in acting as coordinator for European Scientific Advice.
For further information and registration, please visit: